Spentzouris G, Bilitou A, Manga N, McCrink L, Pearson I, Mitchell S, Moss E, Rothwell B. Systematic literature review of cost and data sources for economic evaluations in hypercholesterolaemia and mixed dyslipidaemia from a UK perspective. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

OBJECTIVES This study aimed to identify and critically appraise evidence to inform a cost-effectiveness model for a novel treatment in hypercholesterolaemia and mixed dyslipidaemia.

METHODS A systematic review of literature from January 2015 onwards was conducted to assess economic evaluations and identify utilities, healthcare resource use and cost data to inform health states in an economic model from the UK perspective. Electronic searches in EMBASE, MEDLINE, EconLit, ScHARRUD, NHS EED and the HTA Database were conducted with combinations of MeSH terms and free text. Additional targeted searches were conducted in key conference websites. Inclusion and exclusion criteria were documented using (Population Intervention Comparator Outcome) PICO framework and a modified Preferred Reporting of Systematic Reviews and Meta-Analysis (PRISMA) flow chart. A quality assessment was performed for cost-effectiveness and cost-utility analyses using the Drummond checklist.

RESULTS 144 publications were included: 35 economic evaluations, 58 cost and resource use studies, and 56 utility studies. Studies reported multiple types of data hence counted in multiple categories. Most utility studies contained insufficient granularity in reported data (32%), or conducted in a non-relevant population (30%), however, two were high quality studies that used the EQ-5D and presented data for relevant health states. Most cost studies were representative of the UK setting and aligned with the perspective of National Health Service and Personal Social Services. Five cost and resource use studies were considered suitable for use in an economic model; the remainder were excluded due to non-relevant health states (44%) or inappropriate population (23%).

CONCLUSIONS Although the structure of our economic model was aligned with those previously used in health technology assessments in this indication, only limited new data were identified, yet considered of sufficient quality and relevance to inform our model but highlighting a gap in the current literature and the need for real-world contemporary data.